Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.
Department of Family Medicine, CAPHRI Care And Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13189. Epub 2017 Aug 14.
BACKGROUND: The Rome criteria for irritable bowel syndrome (IBS) have been revised and are expected to apply only to the subset of Rome III IBS subjects with abdominal pain as predominant symptom, occurring at least once a week. The aim of this study was to determine the percentage of Rome III IBS subjects that fulfills Rome IV criteria and to evaluate differences between Rome IV-positive and Rome IV-negative subjects. METHODS: Four hundred and four Rome III IBS subjects completed a 14-day end-of-day symptom diary, the Gastrointestinal Symptom Rating Scale (GSRS), Hospital Anxiety and Depression Scale, and RAND 36-item Short-Form Health Survey (SF-36). Diary-based surrogate Rome IV criteria were defined as occurrence of abdominal pain at least 1 day each week with a severity of ≥2 (mild; definition 1) or ≥3 (considerable; definition 2). KEY RESULTS: Using surrogate Rome IV criteria, 353 (87.4%, definition 1) and 249 (61.6%, definition 2) subjects were defined as Rome IV positive. These patients were more often female, younger, and recruited from secondary/tertiary care compared with Rome IV-negative subjects. They also presented with higher abdominal pain scores and gastrointestinal (GI) symptom severity on both end-of-day diary and GSRS, higher psychological symptom scores, and lower quality of life compared with Rome IV-negative subjects. CONCLUSIONS AND INFERENCES: The Rome IV IBS population likely reflects a subgroup of Rome III IBS patients with more severe GI symptomatology, psychological comorbidities, and lower quality of life. This implies that results from Rome III IBS studies may not be directly comparable to those from Rome IV IBS populations.
背景:罗马标准修订版用于肠易激综合征(IBS),仅适用于罗马 III 型 IBS 中以腹痛为主要症状且每周至少发生一次的患者亚组。本研究旨在确定符合罗马 IV 标准的罗马 III 型 IBS 患者的比例,并评估罗马 IV 阳性和罗马 IV 阴性患者之间的差异。
方法:404 名罗马 III 型 IBS 患者完成了为期 14 天的每日症状日记、胃肠道症状评定量表(GSRS)、医院焦虑抑郁量表和 RAND 36 项简明健康调查问卷(SF-36)。以日记为基础的替代罗马 IV 标准定义为每周至少 1 天出现腹痛,严重程度为≥2(轻度;定义 1)或≥3(明显;定义 2)。
主要结果:使用替代罗马 IV 标准,353 名(87.4%,定义 1)和 249 名(61.6%,定义 2)患者被定义为罗马 IV 阳性。与罗马 IV 阴性患者相比,这些患者更常为女性、更年轻,且主要来源于二级/三级医疗机构。与罗马 IV 阴性患者相比,他们在每日症状日记和 GSRS 上的腹痛评分和胃肠道(GI)症状严重程度更高,心理症状评分更高,生活质量更低。
结论和推断:罗马 IV 型 IBS 人群可能反映了罗马 III 型 IBS 患者中具有更严重 GI 症状、心理合并症和更低生活质量的亚组。这意味着罗马 III 型 IBS 研究的结果可能不能直接与罗马 IV 型 IBS 人群的结果相比较。
Neurogastroenterol Motil. 2017-8-14
Neurogastroenterol Motil. 2017-6-28
Neurogastroenterol Motil. 2015-9
J Gastroenterol Hepatol. 2017-5
PLOS Glob Public Health. 2025-5-22